Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.

Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L.

Schizophr Res. 2018 Feb;192:185-193. doi: 10.1016/j.schres.2017.04.004. Epub 2017 Apr 26.


Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L.

J Clin Psychopharmacol. 2016 Aug;36(4):372-6. doi: 10.1097/JCP.0000000000000535.


Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L.

J Clin Psychiatry. 2015 Mar;76(3):253-62. doi: 10.4088/JCP.14m09416.


Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ.

J Med Econ. 2015;18(8):629-36. doi: 10.3111/13696998.2015.1033424. Epub 2015 Apr 22.


Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.

Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.

Clin Drug Investig. 2018 Aug;38(8):695-702. doi: 10.1007/s40261-018-0647-z.


Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.

Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ.

J Nerv Ment Dis. 2017 Apr;205(4):324-328. doi: 10.1097/NMD.0000000000000646.


Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.

Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon JS, Chen JJ.

Neuropsychiatr Dis Treat. 2017 Aug 17;13:2193-2207. doi: 10.2147/NDT.S134287. eCollection 2017.


Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.

Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw018. doi: 10.1093/ijnp/pyw018. Print 2016 Jul.


An assessment of injection site reaction and injection site pain of 1-month and 3-month long-acting injectable formulations of paliperidone palmitate.

Kern Sliwa J, Savitz A, Nuamah I, Mathews M, Gopal S, Elefant E, Najarian D, Alphs L.

Perspect Psychiatr Care. 2018 Oct;54(4):530-538. doi: 10.1111/ppc.12267. Epub 2018 Feb 14.


Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study.

Savitz AJ, Xu H, Gopal S, Nuamah I, Hough D, Mathews M.

Int Clin Psychopharmacol. 2017 Nov;32(6):329-336. doi: 10.1097/YIC.0000000000000190.


Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.

Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L.

J Affect Disord. 2016 Mar 15;193:381-90. doi: 10.1016/j.jad.2015.12.060. Epub 2015 Dec 31.


Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.

Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L.

Int Clin Psychopharmacol. 2016 Nov;31(6):315-22. doi: 10.1097/YIC.0000000000000141.


Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.

Schreiner A, Caspi A, Bergmans P, Cherubin P, Keim S, Lara E, Pinchuk I, Schuepbach D, Suleman S, Hargarter L.

Psychopharmacology (Berl). 2017 Jan;234(1):3-13. doi: 10.1007/s00213-016-4445-0. Epub 2016 Nov 5.


An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).

Parellada E, Bioque M, Serrano M, Herrera B, GarcĂ­a Dorado M; SHADOW Study Group.

Int J Psychiatry Clin Pract. 2018 Sep;22(3):191-199. doi: 10.1080/13651501.2017.1404112. Epub 2017 Nov 21.


Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.

Schreiner A, Aadamsoo K, Altamura AC, Franco M, Gorwood P, Neznanov NG, Schronen J, Ucok A, Zink M, Janik A, Cherubin P, Lahaye M, Hargarter L.

Schizophr Res. 2015 Dec;169(1-3):393-399. doi: 10.1016/j.schres.2015.08.015. Epub 2015 Oct 1.


Paliperidone Palmitate Improves and Maintains Functioning in Asia-Pacific Patients with Schizophrenia.

Zhang H, Turkoz I, Zhuo J, Mathews M, Tan W, Feng Y.

Adv Ther. 2017 Nov;34(11):2503-2517. doi: 10.1007/s12325-017-0638-0. Epub 2017 Nov 3.


Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Schotte A, Remmerie B, Maruta N, Hough DW.

JAMA Psychiatry. 2015 Aug;72(8):830-9. doi: 10.1001/jamapsychiatry.2015.0241.


Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.

Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai LF, Peters-Strickland T, Perry PP, McQuade RD, Johnson BR, Carson WH, Kane JM.

Schizophr Res. 2014 Nov;159(2-3):415-20. doi: 10.1016/j.schres.2014.09.019. Epub 2014 Oct 3.


Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M.

Schizophr Res. 2010 Feb;116(2-3):107-17. doi: 10.1016/j.schres.2009.10.026. Epub 2009 Dec 2.


Supplemental Content

Support Center